ImmuPharma PLC - Asset Resilience Ratio

Latest as of December 2023: 0.00%

ImmuPharma PLC (IMM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ImmuPharma PLC (IMM) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX-1.00

≈ $-0.00 USD Cash + Short-term Investments

Total Assets

GBX2.72 Million

≈ $331.12 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how ImmuPharma PLC's Asset Resilience Ratio has changed over time. See ImmuPharma PLC (IMM) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ImmuPharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ImmuPharma PLC (IMM) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-1.00	-0.0%
Total Liquid Assets	GBX-1.00	0.00%

Asset Resilience Insights

Limited Liquidity: ImmuPharma PLC maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

ImmuPharma PLC Industry Peers by Asset Resilience Ratio

Compare ImmuPharma PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for ImmuPharma PLC (2016–2022)

The table below shows the annual Asset Resilience Ratio data for ImmuPharma PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-2.08%	GBX-82.56K ≈ $-10.05	GBX3.97 Million ≈ $483.61	+4.68pp
2021-12-31	-6.76%	GBX-405.49K ≈ $-49.34	GBX6.00 Million ≈ $729.76	-5.16pp
2020-12-31	-1.60%	GBX-174.49K ≈ $-21.23	GBX10.92 Million ≈ $1.33K	+12.94pp
2019-12-31	-14.53%	GBX-843.15K ≈ $-102.59	GBX5.80 Million ≈ $705.82	-37.71pp
2016-12-31	23.17%	GBX1.55 Million ≈ $189.18	GBX6.71 Million ≈ $816.39	--

pp = percentage points

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$269.44K

GBX2.21 Billion GBX

Market Cap Rank

#31037 Global

#989 in UK

Share Price

GBX4.41

Change (1 day)

+0.00%

52-Week Range

GBX1.50 - GBX17.60

All Time High

GBX190.00